December 1, 2018 Issue

You don't need to spend countless hours perusing your typical online sources when you have this! Stay informed today by becoming an AARS member and receiving the Hot Topics!

Hot Topics at a Glance

AARS Event

  • Save the Date: 14th Annual AARS Reception, Friday, March 1, 2019 6P – 9PM, Washington, DC

Industry News

  • Sarecycline approved for moderate-to-severe acne.
  • HintMD launches medical-grade skincare subscriptions.

New Medical News

  • Potassium iodide for cutaneous inflammatory disorders: A monocentric, retrospective study. 
  • Apremilast for moderate hidradenitis suppurativa: no significant change in lesional skin inflammatory biomarkers. 
  • Evaluation of medical and surgical treatments for hidradenitis suppurativa using real-life data from the Scandinavian registry (HISREG).
  • In vitro antioxidant and anti-propionibacterium acnes activities of cold water, hot water, and methanol extracts, and their respective ethyl acetate fractions, from sanguisorba officinalis l. roots. 
  • Design, preparation and evaluation of liposomal gel formulations for treatment of acne: In vitro and in vivo studies. 
  • Topical tazarotene gel, 0.1%, as a novel treatment approach for atrophic postacne scars: A randomized active-controlled clinical trial. 
  • Transconjugation of erm(X) conferring high-level resistance of clindamycin for cutibacterium acnes,
  • Survey of acne-related post-inflammatory hyperpigmentation in the Middle East. 
  • Alpha- and gamma-mangostins exhibit anti-acne activities via multiple mechanisms. 
  • Development of rifampicin-indocyanine green-loaded perfluorocarbon nanodroplets for photo-chemo-probiotic antimicrobial therapy. 
  • Potential applications of topical oxygen therapy in dermatology. 
  • Negative pressure wound therapy with instillation and dwell time in the surgical management of severe hidradenitis suppurativa. 

Clinical Reviews

  • Guselkumab in the treatment of severe hidradenitis suppurativa. 
  • Rifampin alone may be enough. Is it time to abandon the classic oral clindamycin - rifampicin combination for hidradenitis suppurativa? 
  • Long-term clinical safety of clindamycin and rifampicin combination for the treatment of hidradenitis suppurativa: strategy to reduce side effects, improving patients' compliance. 
  • Complement, hidradenitis suppurativa and pathogen-driven positive selection. 
  • Failure of tocilizumab in treating two patients with refractory SAPHO syndrome: a case report. 
  • New concepts, concerns, and creations in acne. 
  • Comorbidities in dermatology: What's real and what's not.
  • Botulinum toxin injections may improve scarring. 
  • A dermatological questionnaire for general practitioners with a focus on hidradenitis suppurativa. 

Patient Counseling/Communication

  • Using Google to trend patient interest in botulinum toxin and hyaluronic acid fillers. 


Click Here to Download the AARS Hot Topics Newsletter